ENERGYNEST
30.3.2017 14:32:09 CEST | Business Wire | Press release
Tata Steel operates one of Europe’s largest steel production facilities in IJmuiden / Netherlands. Currently, large energy potentials are released to the atmosphere, through intermittent high temperature exhaust gases. Implicit economic benefits of this waste heat remain untapped. Finding an effective way to recover and reuse this energy will not only yield attractive economic returns, but also significant CO2 emission reductions.
In order to fully utilize such effects, Tata Steel is now commencing the implementation of an EnergyNest Thermal Energy Storage (TES) demo project as a ‘lighthouse initiative’. The IJmuiden demo will utilize exhaust gas energy from steel production to cover own energy demands in the facility – resulting in reduced natural gas consumption and CO2 emissions.
“The steel industry has already undertaken huge efforts to reduce emissions, and to go any further simply requires new technologies. This demo installation is just a first step for Tata’s IJmuiden plant. We are proud to be yet again the global leader for implementing environmentally friendly solutions with a strong business case.” says Gerard Jägers, Program Manager Energy Efficiency. A joint assessment of effects for a full-scale implementation of the EnergyNest throughout the IJmuiden facility shows impressive results: a 500 MWh TES can yield annual savings of 2.3 million GJ of natural gas (65 million Nm3 ) and 130.000 tons of emitted CO2 . EnergyNest CEO Dr. Christian Thiel: “These savings compensate for annual CO2 emissions of 90.000 cars. And at the same time a full-scale implementation offers extremely attractive economics, which supplement such a project with a very healthy business rationale. We are very proud to support Tata Steel in its game-changing approach towards carbon footprint reduction.”
The EnergyNest TES technology is based on globally available materials that are fully recyclable. Due to its very low cost-base, a full-scale implementation in the IJmuiden facility – together with Jord as acting EPC – has a payback of less than three years, based on today’s natural gas prices. Should natural gas prices increase the payback period is reduced to less than two years. Adopting this innovative technology, Tata Steel IJmuiden will strengthen the facility's status as a global technology frontrunner.
About EnergyNest: EnergyNest (EN) is a technology company based in Billingstad, close to the Norwegian capital Oslo. Founded in 2011, EN has developed a unique and patented design for a modular solid-state thermal energy storage (“TES”) systems and a tailored solid state storage medium (HEATCRETE®) that enables a very simple, efficient, and low cost energy storage system (“EN technology”). The EN technology can be applied in various market segments, that require high temperature thermal energy storage for many hours or days. EN’s technology is field proven at the Masdar Institute, UAE.
About Tata Steel: Tata Steel is one of the world leading manufacturers of raw steel, rolled and coated products. It is also one of the world’s most geographically diversified steel producers, serving many demanding markets worldwide, including Aerospace, Automotive, Construction, Consumer Products, Defence & Security, Energy & Power, Lifting & Excavating and Packaging. Tata Steel is committed to the design of more sustainable products that contribute to solutions, which are lighter, last longer and use fewer resources to produce.
About Jord: Jord Oil & Gas Systems B.V. is a Rotterdam based company that designs, manufactures, commissions, and services custom-engineered process equipment, modular skids, and turnkey plants for the steel, oil and gas, chemical and petrochemical industries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005611/en/
Contact:
EnergyNest
Thomas Palkovich
Commercial Director
Mob:
+47 982 08 384
Email: tp@energy-nest.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom